We are live on ! Find out more
CLRB icon

Cellectar Biosciences
CLRB

14 hedge funds and large institutions have $4.34M invested in Cellectar Biosciences in 2019 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

4,801% more capital inflows, than outflows

Capital inflows: $4.06M | Capital outflows: $82.9K

300% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 1

100% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 1

27% more funds holding

Funds holding: 11 → 14 (+3)

14.97% more ownership

Funds ownership: 7.44% → 22.41% (+15%)

Holders
14
Holders Change
+3
Holders Change %
+27.27%
% of All Funds
0.3%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
4
Increased
2
Reduced
1
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Boxer Capital
Boxer Capital
California
+$2.09M
2
Tang Capital Management
Tang Capital Management
California
+$1.55M
3
CVI Holdings
CVI Holdings
Delaware
+$241K
4
Renaissance Technologies
Renaissance Technologies
New York
+$151K
5
Private Advisor Group
Private Advisor Group
New Jersey
+$30.7K

Top Sellers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
-$42K
2
Morgan Stanley
Morgan Stanley
New York
-$40.9K

CLRB Hedge Fund Activity: Q2 2019 in Review

14 of the 4,626 institutional investors tracked by Wall St. Rank reported a position in Cellectar Biosciences (CLRB) for Q2 2019, worth a combined $4.34M — up 631% from $593K a quarter earlier.

Buyers outnumbered sellers: 4 funds opened new CLRB positions and 1 closed out — a net gain of 3 holders — while 2 added to existing stakes and 1 trimmed.

The largest buyer was Boxer Capital, opening a new position worth an estimated $2.09M. The largest seller was Citadel Advisors, exiting entirely with an estimated $42K sold.

  • 14 institutional investors held Cellectar Biosciences (CLRB) as of Q2 2019, up from 11 in Q1 2019.
  • Funds reported $4.34M of Cellectar Biosciences stock for Q2 2019, up 631% quarter-over-quarter.
  • 4 funds opened new Cellectar Biosciences positions in Q2 2019 and 1 closed out, a net change of +3 holders.
  • The largest Cellectar Biosciences buyer in Q2 2019 was Boxer Capital, an estimated $2.09M added.
  • The largest Cellectar Biosciences seller in Q2 2019 was Citadel Advisors, an estimated $42K sold.

Based on aggregated 13F filings for Q2 2019.